NASDAQ:RGNX

REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore
·····

REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore

REGENXBIO Inc shares slipped 0.6% to $6.97 in late morning Nasdaq trading Monday, with no new company news or filings in the past two days. The stock tracked weakness in biotech peers, including Sarepta, as investors focused on RGX-202 trial progress and the company’s cash runway. REGENXBIO last reported $150.5 million in cash at March 31, enough to fund operations into early 2027.
June 1, 2026

Stock Market Today

  • Wise Faces Investigation Over Alleged Money Laundering Controls in Europe
    June 1, 2026, 1:50 PM EDT. UK-based money transfer company Wise is under investigation by Belgian prosecutors over alleged money laundering control failures in its European operations, not its UK business. The probe focuses on suspicions that Wise accounts facilitated around €500 million in suspicious transactions across 30 European countries. Wise, which recently shifted its primary stock listing to the US Nasdaq, stated it is cooperating fully but has not received any formal findings yet. Shares plunged 17.5%, wiping more than £1 billion off its market value. The investigation could affect customer trust and lead to regulatory penalties if oversight lapses are confirmed. Founded in 2011, Wise serves over 19 million customers globally with 4.7 million daily transactions.